ES2116880A1 - Farmacos y composiciones farmaceuticas para su uso en el tratamiento de enfermedades. - Google Patents

Farmacos y composiciones farmaceuticas para su uso en el tratamiento de enfermedades.

Info

Publication number
ES2116880A1
ES2116880A1 ES09500774A ES9500774A ES2116880A1 ES 2116880 A1 ES2116880 A1 ES 2116880A1 ES 09500774 A ES09500774 A ES 09500774A ES 9500774 A ES9500774 A ES 9500774A ES 2116880 A1 ES2116880 A1 ES 2116880A1
Authority
ES
Spain
Prior art keywords
psychosis
parkinson
disease
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09500774A
Other languages
English (en)
Other versions
ES2116880B1 (es
Inventor
David John Heal
Patricia Lesley Needham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2116880A1 publication Critical patent/ES2116880A1/es
Application granted granted Critical
Publication of ES2116880B1 publication Critical patent/ES2116880B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FARMACOS Y COMPOSICIONES FARMACEUTICAS PARA SU USO EN EL TRATAMIENTO DE ENFERMEDADES. EL USO DE COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO PARA TRATAR DISQUINESIAS INDUCIDAS POR FARMACOS, ENFERMEDAD DE PARKINSON, PSICOSIS DOPAMINOMIMETICAS EN LA ENFERMEDAD DE PARKINSON, Y PSICOSIS, EN EL QUE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN COMPUESTO DE FORMULA I O SALES Y METABOLITOS FARMACEUTICAMENTE ACEPTABLES DEL MISMO, EN LA QUE N ES UN NUMERO ENTERO DE 1 A 6; Y R REPRESENTA H, HALOGENO, ALQUILO DE 1 A 4, UN GRUPO HETEROARILO, SULFO, SULFAMOILO N-SUSTITUIDO O N,N-DISUSTITUIDO, NITRO, HIDROXI, OXO, ALCOXI DE 1 A 4, CIANO, ALQUILCARBOXILATO DE 1 A 4, UN GRUPO ARILO O ARILO SUSTITUIDO, O UN GRUPO AMINO O AMINO SUSTITUIDO DE FORMULA EN LA QUE R1, Y R2, QUE PUEDEN SER IGUALES O DIFERENTES, REPRESENTAN H, ALQUILO, ARILO, ALQUILCARBONILO, ARILCARBONILO, ALQUILSULFONILO O ARILSULFONILO, CONTENIENDO LOS FRAGMENTOS ALQUILO DE ESTOS GRUPOS DE 1 A 4 ATOMOS DE CARBONO, ES ADMINISTRADA JUNTO CON UN DILUYENTE O VEHICULO ACEPTABLE FARMACEUTICAMENTE.
ES09500774A 1994-04-23 1995-04-21 Farmacos y composiciones farmaceuticas para su uso en el tratamiento de enfermedades. Expired - Fee Related ES2116880B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408084A GB9408084D0 (en) 1994-04-23 1994-04-23 Medical treatment

Publications (2)

Publication Number Publication Date
ES2116880A1 true ES2116880A1 (es) 1998-07-16
ES2116880B1 ES2116880B1 (es) 1999-08-01

Family

ID=10754011

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09500774A Expired - Fee Related ES2116880B1 (es) 1994-04-23 1995-04-21 Farmacos y composiciones farmaceuticas para su uso en el tratamiento de enfermedades.

Country Status (5)

Country Link
AU (1) AU2137595A (es)
ES (1) ES2116880B1 (es)
GB (1) GB9408084D0 (es)
WO (1) WO1995028933A1 (es)
ZA (1) ZA953237B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656762A (en) * 1990-12-28 1997-08-12 Neurogen Corporation 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497658A1 (fr) * 1991-01-25 1992-08-05 Laboratorios Del Dr. Esteve, S.A. Utilisation de dérivés 1-H-azole-(omega-(4-(2-pyrimidinyl)-1-pipérazinyl)-alkyl) pour la préparation de médicaments destinés au traitement des troubles des fonctions cognitives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497658A1 (fr) * 1991-01-25 1992-08-05 Laboratorios Del Dr. Esteve, S.A. Utilisation de dérivés 1-H-azole-(omega-(4-(2-pyrimidinyl)-1-pipérazinyl)-alkyl) pour la préparation de médicaments destinés au traitement des troubles des fonctions cognitives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AHLENIUS, S. Antipsychotic-like properties of the 5-HT1A Agonist 8-OH-DPAT in the rat. Pharmacology & Toxycology. 1989, Vol. 64, pßginas 3-5 * Todo el documento * *
HAJ-DAHMANE et al. Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat. European J. of Pharmacology. 1994, Vol. 255, n‘ 1-3, pßginas 185-196 * Todo el documento * *
INVERNIZZI et al. 8-Hidroxy-2-(di-N-propylamino) tetralin, a selective serotonin 1A receptor agonist, blocks haloperidol-induced cßtalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology. 1988, Vol. 27, N‘ 5, pßginas 515-518 * Todo el documento * *
WOLTERS, E.C. et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990, Vol. 40, n‘ 5, pßginas 832-834 * Todo el documento * *

Also Published As

Publication number Publication date
GB9408084D0 (en) 1994-06-15
ES2116880B1 (es) 1999-08-01
AU2137595A (en) 1995-11-16
ZA953237B (en) 1995-12-28
WO1995028933A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
PT94925A (pt) Processo para a preparacao de derivados de tiazol e de composicoes farmaceuticas que os contem
CA2107014A1 (en) Therapeutic Agent for Parkinson's Disease
NZ332658A (en) Halo-substituted bis-indolylmaleimide derivatives and pharmaceutical compositions
TW225513B (es)
AU6976394A (en) Aminoacid derivatives as no synthase inhibitors
ES8801618A1 (es) Un procedimiento para preparar derivados de arilciclobutilalquilamina
NZ333015A (en) 2-(1H-indol-2-yl)-5-[(2H-pyrrol-2-ylidene)methyl]-pyrrole derivatives, process for their preparation and medicaments
ES2116880A1 (es) Farmacos y composiciones farmaceuticas para su uso en el tratamiento de enfermedades.
FI955429A0 (fi) 1-aryylisykloalkyylisulfideja, sulfoksideja ja sulfoneja depression, tuskatilojen ja Parkinsonin taudin hoitamiseksi
IE56000B1 (en) 1-arylcyclobutylalkylamine compounds
AU561772B2 (en) Cyclobutyl methylamine derivatives
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
CO4700463A1 (es) Compuestos sustituidos de dihidroimidazo [2,1-b] tiazol y dihidro-5h-tiazol(3,2-a)pirimidina, procedimientos para su preparacion
AU539177B2 (en) Amino alkoxy pyrazoles
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
ES8506722A1 (es) Un procedimiento para la preparacion de derivados de -lactama
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
EP2077264A3 (en) Taxane derivatives and a process for the preparation thereof
CA2162706A1 (en) 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: LABORATORIOS DEL DR. ESTEVE, S.A.

EC2A Search report published

Date of ref document: 19980716

Kind code of ref document: A1

Effective date: 19980716

FD1A Patent lapsed

Effective date: 20020401